Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
002675.SZ · SHZ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | CN¥755,972 | CN¥644,418 | CN¥1,021,624 | CN¥826,611 |
| Short-Term Investments | CN¥148,542 | CN¥20,115 | CN¥27,327 | CN¥129,273 |
| Receivables | CN¥948,724 | CN¥794,075 | CN¥883,529 | CN¥875,482 |
| Inventory | CN¥646,221 | CN¥903,864 | CN¥1,078,053 | CN¥952,528 |
| Other Curr. Assets | CN¥41,029 | CN¥115,213 | CN¥182,187 | CN¥115,874 |
| Total Curr. Assets | CN¥2,567,649 | CN¥2,477,686 | CN¥3,192,720 | CN¥2,899,769 |
| Property Plant & Equip (Net) | CN¥2,334,898 | CN¥2,146,706 | CN¥1,963,803 | CN¥1,616,073 |
| Goodwill | CN¥2,500,810 | CN¥2,544,192 | CN¥2,329,646 | CN¥2,373,473 |
| Intangibles | CN¥518,230 | CN¥425,358 | CN¥321,968 | CN¥308,971 |
| Long-Term Investments | CN¥207,513 | CN¥212,919 | CN¥163,770 | CN¥114,096 |
| Tax Assets | CN¥94,889 | CN¥88,034 | CN¥63,708 | CN¥58,615 |
| Other NC Assets | CN¥410,689 | CN¥187,459 | CN¥141,350 | CN¥285,286 |
| Total NC Assets | CN¥6,067,029 | CN¥5,604,668 | CN¥4,984,245 | CN¥4,756,513 |
| Other Assets | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Total Assets | CN¥8,634,678 | CN¥8,082,354 | CN¥8,176,965 | CN¥7,656,281 |
| Liabilities | – | – | – | – |
| Payables | CN¥588,407 | CN¥876,023 | CN¥1,331,808 | CN¥1,052,226 |
| Short-Term Debt | CN¥448,880 | CN¥331,384 | CN¥438,129 | CN¥522,327 |
| Tax Payable | CN¥70,018 | CN¥77,692 | CN¥97,593 | CN¥66,625 |
| Deferred Revenue | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Other Curr. Liab. | CN¥199,814 | CN¥293,674 | CN¥363,151 | CN¥274,174 |
| Total Curr. Liab. | CN¥1,753,956 | CN¥1,951,726 | CN¥2,393,379 | CN¥2,042,949 |
| LT Debt | CN¥301,858 | CN¥249,206 | CN¥232,602 | CN¥520,364 |
| Deferred Rev, NC | CN¥195,685 | CN¥233,291 | CN¥240,273 | CN¥47,328 |
| Deferred Tax Liab, NC | CN¥17,406 | CN¥18,099 | CN¥18,614 | CN¥16,760 |
| Other NC Liab. | CN¥960,423 | CN¥223,340 | CN¥2,220 | CN¥2,220 |
| Total NC Liab. | CN¥1,509,254 | CN¥735,004 | CN¥501,241 | CN¥589,562 |
| Other Liabilities | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Cap. Leases | CN¥33,883 | CN¥11,068 | CN¥7,531 | CN¥2,890 |
| Total Liabilities | CN¥3,263,210 | CN¥2,686,730 | CN¥2,894,620 | CN¥2,632,511 |
| Equity | – | – | – | – |
| Pref Stock | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Common Stock | CN¥824,596 | CN¥824,596 | CN¥824,596 | CN¥802,214 |
| Retained Earnings | CN¥1,363,507 | CN¥1,362,633 | CN¥1,299,974 | CN¥1,108,320 |
| AOCI | CN¥294,086 | CN¥247,452 | CN¥4,845 | CN¥169,997 |
| Other Equity | CN¥0 | CN¥0 | CN¥241,934 | CN¥0 |
| Total Equity | CN¥4,480,445 | CN¥4,775,401 | CN¥4,748,680 | CN¥4,397,415 |
| Supplemental Information | – | – | – | – |
| Minority Interest | CN¥891,023 | CN¥620,222 | CN¥533,666 | CN¥626,355 |
| Total Liab. & Tot. Equity | CN¥8,634,678 | CN¥8,082,354 | CN¥8,176,965 | CN¥7,656,281 |
| Net Debt | -CN¥5,234 | -CN¥63,828 | -CN¥350,893 | CN¥216,080 |